Last updated: February 13, 2026
Product Overview
NDC 00078-0423 corresponds to Gardasil 9, a human papillomavirus (HPV) vaccine manufactured by Merck & Co. Introduced in 2014, Gardasil 9 covers nine HPV types and has become the primary HPV vaccine in most markets.
Market Size and Growth Trends
The global HPV vaccine market was valued at approximately $4 billion in 2021 and is projected to reach $6 billion by 2027, with a compound annual growth rate (CAGR) of around 7.2% [1]. Growth Drivers include increased awareness of HPV-related cancers, expanding vaccination programs, and pediatric immunization mandates.
Market Adoption and Geographic Breakdown
- United States: Largest market, with over 80 million doses administered since 2016, aided by CDC recommendations and school mandates.
- Europe: Growing adoption, especially in France, Germany, and Italy, driven by national immunization programs.
- Emerging Markets: Rapid expansion, particularly in China and India, where immunization infrastructure improves and public health initiatives increase.
Competitive Landscape
Niched primarily to Gardasil 9, off-label use of earlier vaccines (Gardasil and Cervarix) remains limited due to efficacy differences. Other players, such as Cervarix (GSK), hold smaller market share in certain regions. Niche competitors focus on therapeutic HPV vaccines, although none yet have widespread approval.
Pricing Trends
- United States: The average wholesale price (AWP) for a three-dose series ranges from $150 to $180. Actual transaction prices may be lower owing to negotiations, discounts, or insurance coverage.
- European Union: Price per dose averages €80 to €110 ($88 to $121), influenced by national health authority negotiations.
- Emerging Markets: Prices vary significantly, ranging from $30 to $80 per dose, depending on procurement volume and local policies.
Price Projections (Next 5 Years)
- United States: Prices are expected to remain stable, with minor decreases driven by increased competition from biosimilars or alternative delivery routes. Projection: $140–$160 per series.
- Europe: Prices likely to decline modestly by 4-6% annually due to competitive bidding and health system negotiations. Projection: €75–€100 per dose.
- Emerging Markets: Prices may decline marginally as manufacturing costs decrease and procurement volume increases. Projection: $25–$70 per dose.
Regulatory and Policy Influences
- US CDC & ACIP: Reaffirmed HPV vaccination for boys and girls, impacting demand stability.
- European Medicines Agency (EMA): Continues approval expansions, supporting market expansion.
- Developing Countries: Adoption driven by GAVI funding, which could lower prices further and expand access.
Risks and Opportunities
- Risks: Market saturation, potential biosimilar entry, and policy shifts affecting vaccination mandates.
- Opportunities: Expansion into adult vaccination, therapeutic HPV vaccines in development, and integration with broader cancer prevention programs.
Key Takeaways
- The HPV vaccine market, led by Gardasil 9, continues to grow, especially in developed regions.
- Pricing in the US ranges $150–$180 for the full series, with future stability expected.
- European prices are slightly lower but declining; emerging markets see more variable prices.
- Policy mandates and GAVI funding influence uptake, creating opportunities.
- Competitive pressures and biosimilar developments could impact pricing and market share.
FAQs
1. What factors influence HPV vaccine prices?
Market demand, procurement volume, negotiations by health authorities, regional policies, and manufacturing costs.
2. How does Gardasil 9 compare to earlier HPV vaccines?
Gardasil 9 provides broader protection against HPV types, making it the preferred vaccine in most markets, leading to higher market share and price stability.
3. Are there biosimilar equivalents for Gardasil 9?
As of 2023, no biosimilars have received marketing approval; development remains ongoing.
4. What is the outlook for vaccination policy in low-income countries?
GAVI support facilitates access, potentially increasing vaccination rates and influencing demand and pricing.
5. How might new therapeutic HPV vaccines impact this market?
If approved, therapeutic vaccines could shift focus from prevention to treatment, altering market dynamics.
Citations
[1] Expert Market Research. "HPV Vaccines Market Size, Share & Trends Analysis Report." 2022.
